A prospective, randomized, double-blind, placebo-controlled, parallel group, multi-center, 52-week trial to assess the efficacy and safety of adjunct mycophenolate mofetil (MMF) to achieve remission with reduced corticosteroids in subjects with active pemphigus vulgaris